Reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
In 2001, a team at the University of Rome La Sapienza conducted a neutralization-reionization mass spectrometry experiment to investigate the structure of free O4 molecules. Their results did not agree with either of the two proposed molecular structures, but they did agree with a complex between two O2 molecules, one in the ground state and the other in a specific excited state. A chain structure is theoretically possible, but attempts at advanced computational analysis found that it rearranged to the D2d structure.
Mary Osborn (born in 1940) is a L'Oréal-UNESCO Women in Science Award-winning English cell biologist who, until she stopped running an active laboratory in 2005, was on the scientific staff at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. Osborn established two techniques frequently used by cell biologists. She pioneered both molecular weight determination of proteins using SDS PAGE and immunofluorescence microscopy. Osborn also used the immunofluorescence microscopy method to work out the details of the eukaryotic cytoskeleton. Small differences in the intermediate filament constituents helped her distinguish differentiated cells from each other. She also found intermediate filament immunofluorescence differences between normal versus cancer cells. Mary Osborn has been a prominent spokesperson for women in science.
=== Adhesive organ === On the terminal region of the 5th tarsal segment, the C. vomitoria contain pulvilli, which are the cushion-like hairy feet on insects and many arthropods located at base of their two claws. The hair that project from the ventral surface is the key for the adhesion abilities of these flies. Additionally, they have large claws that help to hold on to irregular surfaces to prevent falling. Calliphora vomitoria, like other blowflies, also secrete non-volatile lipids through the hairs that are important for further adhesion. By a combination of the physical grip of the claws and hairs and the surface tension created by the lipid secretions, they are able to adhere to smooth surfaces with ease.
Sources: en.wikipedia.org
In the United States, Utah started screening for GAMT deficiency in all newborns in 2015. New York started screening newborns in late 2018. In 2020, a GAMT-positive infant was identified via newborn screening in Utah, thus providing evidence that a case could be identified from newborn screening. A second infant was identified in New York in 2021. In 2022, a federal advisory committee voted to include GAMT in the Recommended Universal Screening Panel starting in January 2023. In addition to New York and Utah, California, Pennsylvania, Connecticut, Delaware, and Michigan all currently screen for GAMT. Around the world, the state of Victoria, Australia began screening for GAMT in 2004, leading to the diagnosis of a newborn at birth in 2022. In Canada, the provinces of Ontario and British Columbia screen for GAMT.
=== Winning streak === Next, Pudzian faced former bodybuilder Erko Jun on 9 November 2019 at KSW 51: Croatia. He won the bout via second round TKO. Pudzianowski was then scheduled to headline KSW 53 against Quentin Domingos on 21 March 2020 before the bout was scrapped due to Pudzianowski's injury. Pudzianowski was set to return after a fifteen month layoff against the undefeated Senegalese heavyweight Serigne Ousmane at KSW 59: Fight Code on 20 March 2021. However, on the day of the fight, Ousmane Dia suffered an acute appendicitis attack and had to be hospitalized. Stepping in on just a few hours notice was Serbia's Nikola Milanovic. Pudzianowski won the bout via TKO in the first round. Pudzianowski faced KSW 1 tournament winner Łukasz Jurkowski on 5 June 2021 at KSW 63: Crime of The Century. Pudzianowski won the fight via TKO in the 3rd round. The fight with Serigne Ousmane Dia was then rebooked and took place at KSW 64: Przybysz vs. Santos on 23 October 2021. Pudzianowski won the fight via knockout 18 seconds into round one. Pudzianowski faced former KSW Middleweight champion Michał Materla at KSW 70: Pudzianowski vs. Materla on 28 May 2022. He won the bout in the first round, knocking out Materla with an uppercut. He was awarded the Knockout of the Night bonus with the win. Pudzianowski faced former two-division champion Mamed Khalidov at KSW 77: Khalidov vs. Pudzianowski on 17 December 2022. Pudzian's 6-win streak was ended after he tapped to ground and pound in the first round.
Penile measurements vary, with studies that rely on self-measurement reporting a significantly higher average size than those which rely on measurements taken by health professionals. A 2015 systematic review of 15,521 men in which the subjects were measured by health professionals showed that the average length of an erect human penis is 13.12 cm (5.17 inches) long, while the average circumference of an erect human penis is 11.66 cm (4.59 inches). Among all primates, the human penis is the largest in girth, but is comparable to the chimpanzee penis and the penises of certain other primates in length. Penis size is affected by genetics, but also by environmental factors such as fertility medications and chemical/pollution exposure.
11 February – Azhar Ali, Labour's candidate in the Rochdale by-election, apologises after a recording of him reportedly saying that Israel had "allowed" the deadly attack by Hamas gunmen on 7 October was obtained by The Mail on Sunday. Labour condemns his remarks but continues to offer its support to his candidacy. 12 February – Labour withdraws its support for Rochdale candidate Azhar Ali. Tracey Crouch, MP for Chatham and Aylesford, announces she is standing down from Parliament at the next general election. Prime Minister Rishi Sunak appears on an hour long GB News People's Forum, where a selected audience of undecided voters are invited to ask him questions. The programme is presented by Stephen Dixon. 13 February – Labour withdraws its support for Graham Jones, the former MP for Hyndburn, who was going to contest the seat at the next general election, after it emerges he attended a meeting at which Azhar Ali made comments about Israel. 14 February – Former Labour Party leader Neil Kinnock endorses Vaughan Gething to lead Welsh Labour as the next First Minister of Wales. Conservative MP Tobias Ellwood tells BBC Radio 4's PM programme that politicians cannot be viewed as "fair game" after a large-scale pro-Palestinian protest outside his family home. 15 February – By-elections take place in Wellingborough and Kingswood. Labour's Gen Kitchen takes Wellingborough, the Conservative Peter Bone's former seat, which he had held with a majority of more than 18,000.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.